Delayed False Elevation of Circulating Tacrolimus Concentrations after Cord Blood Transplantation in a Patient with Myelodysplastic Syndrome
-
- Hayashi Kiyohito
- Department of Hematology, Kawasaki Medical School, Japan
-
- Tasaka Taizo
- Department of Hematology, Kawasaki Medical School, Japan
-
- Hirose Tadashi
- Department of Hematology, Kawasaki Medical School, Japan
-
- Furukawa Satoko
- Department of Laboratory Medicine, Kawasaki Medical School, Japan
-
- Kohguchi Katsunori
- Department of Laboratory Medicine, Kawasaki Medical School, Japan
-
- Matsuhashi Yoshiko
- Department of Hematology, Kawasaki Medical School, Japan
-
- Wada Hideho
- Department of Hematology, Kawasaki Medical School, Japan
-
- Tohyama Kaoru
- Department of Laboratory Medicine, Kawasaki Medical School, Japan
-
- Sugihara Takashi
- Department of Hematology, Kawasaki Medical School, Japan
Search this article
Abstract
We herein describe the case of a 60-year-old man with a history of Behçet's disease and myelodysplastic syndrome who received cord blood transplantation (CBT). The patient was given anti-thymocyte globulin conditioning and tacrolimus to prevent graft-versus-host disease. Two months after CBT, his blood Tac concentration measured by an antibody-conjugated magnetic immunoassay (ACMIA) was found to have increased >4-fold, even after the Tac treatment was stopped. This false response was caused by the interference of endogenous heterophilic antibodies with ACMIA. Therefore, physicians must be aware of possible false ACMIA results for patients with a history of autoimmune disease and/or treated by xenogeneic antibody therapy.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 53 (22), 2635-2638, 2014
The Japanese Society of Internal Medicine